Deals
Gilead Lifts 2026 Product Sales Outlook To $31.0 Billion-$31.3 Billion, But Still Guides To A Loss
HIV sales rose 18% in the third quarter, yet $12.4 billion in acquired research charges widen the projected full-year loss per share.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Deals
HIV sales rose 18% in the third quarter, yet $12.4 billion in acquired research charges widen the projected full-year loss per share.
SEC Filings
KLA has accrued $20.2 million of the charge, which lifted its effective tax rate to 15.1% from 12.0% in the June quarter.
Earnings
The glucose-monitor maker's U.S. revenue grew 14% in the third quarter, and it lifted 2026 margin guidance.
SEC Filings
The landlord took over 894 homes and paid $196.9 million to do it, while buybacks and revolver borrowing both grew.
SEC Filings
The drug developer's research spending fell to $101.9 million, but an FDA hold on new opakalim enrollment hangs over its biggest licensing deal.
SEC Filings
Hatto will stay on as principal accounting officer through his retirement date, and the filing says no disagreement with GM prompted the move.
SEC Filings
The quarterly cash dividend goes to Series A preferred holders of record on November 15 and is payable December 1.
SEC Filings
The Unified Patent Court ruled the '265 patent invalid, ending Enanta's infringement case covering 18 EU member states.
Earnings
The biotech still targets a third-quarter 2027 readout for its Dravet trial and says $358.8 million in cash lasts into early 2028.
SEC Filings
Houle stays on as an advisor after leaving the CFO job, with his last day set for March 31, 2027.
Earnings
Third-quarter earnings reached $1.66 a share, but operating cash flow guidance fell to $230 million to $250 million.
Earnings
Adjusted EBITDA slipped to $543 million as the realized methanol price eased, but the company guided to a higher fourth quarter.